The effect of sulforaphane on autism spectrum disorder: systematic review and meta-analysis
DOI:
https://doi.org/10.17179/excli2025-8239Keywords:
autism spectrum disorder, meta-analysis, randomized controlled trial, sulforaphaneAbstract
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder lacking effective treatments. This systematic review and meta-analysis assesses the efficacy and safety of sulforaphane (SFN) for ASD. Eight databases were searched from inception to September 2024, identifying six randomized controlled trials for inclusion. Efficacy outcomes included ASD symptoms measured by the mean difference (MD) or standardized mean difference (SMD), while safety outcomes included adverse events measured by relative risk. Risk of bias was assessed using the Cochrane tool, and evidence certainty was evaluated via the Grade of Recommendations Assessment Development and Evaluation (GRADE). Results showed that SFN significantly improved total symptoms (SMD = -0.27, 95 % confidence interval (CI), -0.42, -0.12), aberrant behavior (SMD = -0.43, 95 % CI, -0.66, -0.19), hyperactivity (SMD = -0.58, 95 % CI, -1.03, -0.13), social interaction (SMD = -0.43, 95 % CI, -0.59, -0.27), social communication (SMD = -0.24, 95 % CI, -0.35, - 0.12), and restricted and repetitive behaviors (RRB) (SMD = -0.16, 95 % CI, -0.31, -0.00). Effects on irritability, anxiety, sensory sensitivity, total social skills, social awareness, social cognition, and social motivation were not statistically significant. Adverse events were similar between intervention and control groups. In conclusion, SFN shows potential in improving ASD symptoms without significant adverse effects. However, results should be interpreted cautiously due to potential influences from assessment tools, outcome assessors, and treatment duration. Further research is needed to confirm the long-term efficacy and safety of SFN for ASD.
Downloads
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Rui Wang, Zhenhui Ren, Yamin Li
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
- The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
- The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
- Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
- The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).
